6 results
• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…
This study will evaluate the antitumor activity of RAD001 versus placebo in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC).
This study will evaluate the antitumor activity of RAD001 versus placebo in patients with angiomyolipoma associated with either TSC or LAM.
The primary objectives of this study are: - To evaluate the efficacy of GFT505 80mg and GFT505 120mg once daily (according to adaptive design, after 6-month interim safety analysis of the 80mg data on at least 50% of patients) for 52 weeks versus…
The primary objective of this study is to determine histological ablative efficacy by absence of vital (tumour) cells in the treated prostate zone with (multi)fibre setup in men with PCa scheduled for radical prostatectomy. The secondary objectives…
The primary objective of this study is to prove feasibility and safety of TPLA for LUTS due to BPO in healthy men. The secondary objectives are to determine functional voiding, erectile outcomes and changes on imaging.